The global in vitro diagnostics (IVD) market is estimated at approximately USD 99.51 billion in 2025 and is projected to grow at a CAGR of 4.94% to reach approximately USD 132.9 billion by 2031. The 2025 base is a synthesis of nine published third-party estimates, which span a wide range because publishers define the market differently, and the report documents how they were reconciled to a common definition.
The market is segmented by test technology into immunoassays (about 28% of 2025 value), molecular assays (24%), the core lab and clinical chemistry (17%), point-of-care tests (12%), microbiology and virology, hematology, coagulation, histology and cytology, and blood banking. It is also segmented by application and test area. Regional demand is led by North America (about 42% of 2025 value), with Europe and Asia Pacific each at about 24%, Latin America at 6% and Middle East & Africa at 4%. Country forecasts cover 21 countries.
Aging populations and the rising burden of chronic and infectious disease, the shift to molecular and decentralized point-of-care testing, growth in oncology and genomic diagnostics, and expanding laboratory automation underpin the forecast. Reimbursement pressure, volume-based procurement in China, regulatory requirements such as the EU IVDR, and post-pandemic normalization of respiratory testing act as restraints. The report profiles 23 companies from primary-source FY2025 data, including bioMérieux, Abbott, Roche Diagnostics, Siemens Healthineers, Danaher, Thermo Fisher Scientific, BD, Bio-Rad and QIAGEN, and includes Porter's Five Forces, PESTLE and SWOT analyses and a long-range outlook.
The market is segmented by test technology into immunoassays (about 28% of 2025 value), molecular assays (24%), the core lab and clinical chemistry (17%), point-of-care tests (12%), microbiology and virology, hematology, coagulation, histology and cytology, and blood banking. It is also segmented by application and test area. Regional demand is led by North America (about 42% of 2025 value), with Europe and Asia Pacific each at about 24%, Latin America at 6% and Middle East & Africa at 4%. Country forecasts cover 21 countries.
Aging populations and the rising burden of chronic and infectious disease, the shift to molecular and decentralized point-of-care testing, growth in oncology and genomic diagnostics, and expanding laboratory automation underpin the forecast. Reimbursement pressure, volume-based procurement in China, regulatory requirements such as the EU IVDR, and post-pandemic normalization of respiratory testing act as restraints. The report profiles 23 companies from primary-source FY2025 data, including bioMérieux, Abbott, Roche Diagnostics, Siemens Healthineers, Danaher, Thermo Fisher Scientific, BD, Bio-Rad and QIAGEN, and includes Porter's Five Forces, PESTLE and SWOT analyses and a long-range outlook.
Table of Contents
1. Executive Summary2. Industry Overview & Forecast
3. Market Segmentation by Type
4. Market Segmentation by Application
5. Regional Market Forecast
6. Country-Level Market Forecast
7. Growth Drivers & Inhibitors
8. Key Company Profiles (23 companies including bioMérieux, Abbott, Roche Diagnostics, Siemens Healthineers, Danaher, Thermo Fisher Scientific, BD, Bio-Rad, QIAGEN, Hologic)
9. Competitive Landscape
10. Porter's Five Forces Analysis
11. PESTLE Analysis
12. SWOT Analysis
13. Future Trends & Outlook
Companies Mentioned
- bioMérieux S.A.
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd (Roche Diagnostics)
- Siemens Healthineers AG
- Danaher Corporation
- Thermo Fisher Scientific Inc.
- Becton, Dickinson and Company (BD)
- Bio-Rad Laboratories, Inc.
- Sysmex Corporation
- QIAGEN N.V.
- Agilent Technologies Inc.
- Bruker Corporation
- DexCom, Inc.
- Exact Sciences Corporation
- Hologic, Inc.
- Illumina, Inc.
- Natera, Inc.
- QuidelOrtho Corporation
- Revvity, Inc.
- Werfen
- Seegene Inc.
- Wiener Laboratorios S.A.I.C.
- Wama Diagnóstica Ltda.
